<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131075">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845077</url>
  </required_header>
  <id_info>
    <org_study_id>1288.8</org_study_id>
    <nct_id>NCT01845077</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets</brief_title>
  <official_title>Relative Bioavailability of Two Newly Developed Extended Release FDC Tablet Strengths (5mg/1000mg and 2.5 mg/750 mg) of Linagliptin/Metformin Extended Release Compared With the Free Combination of Linagliptin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed
      fixed dose combination (FDC) tablets containing linagliptin &amp; metformin and the single
      tablets of linagliptin and metformin when administered singularly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours); Linagliptin</measure>
    <time_frame>up to 72 h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma); Linagliptin</measure>
    <time_frame>up to 72 h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin</measure>
    <time_frame>up to 72 h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax; Metformin</measure>
    <time_frame>up to 72 h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Linagliptin</measure>
    <time_frame>up to 72 h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin</measure>
    <time_frame>up to 72 h post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin, fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 single tablets under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Linagliptin/1500 mg Metformin FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 FDC tablets under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Linagliptin/1500 mg Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 single tablets under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination(FDC) tablet under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 single tablets under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg Linagliptin/1000mg Metformin, FDCfed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 FDC tablet under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2x500 mg Metformin (Glumetza)</intervention_name>
    <description>2 tablets</description>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Linagliptin/1000 mg Metformin FDC</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>5mg Linagliptin/1000mg Metformin, FDCfed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Linagliptin (Tradjenta)</intervention_name>
    <description>1 tablet</description>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Linagliptin (Tradjenta)</intervention_name>
    <description>1 tablet</description>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3x500 mg Metformin (Glumetza)</intervention_name>
    <description>3 tablets</description>
    <arm_group_label>5 mg Linagliptin/1500 mg Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Linagliptin (Tradjenta)</intervention_name>
    <description>1 tablet</description>
    <arm_group_label>5 mg Linagliptin/1500 mg Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 x 500 mg Metformin (Glumetza)</intervention_name>
    <description>2 tablets</description>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Linagliptin/1000mg Metformin FDC</intervention_name>
    <description>FDC Tablet</description>
    <arm_group_label>5 mg Linagliptin/1000 mg Metformin FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 x 2.5 mg Linagliptin/750 mg Metformin FDC</intervention_name>
    <description>2 FDC tablets</description>
    <arm_group_label>5 mg Linagliptin/1500 mg Metformin FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males or females

          2. Age 18 -50 years (incl)

          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)

          4. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

        Any deviation from healthy condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1288.8.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 7, 2013</lastchanged_date>
  <firstreceived_date>April 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BI 1356</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
